Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14175937 | 0.90 | MAPT (0.31) | MAPTPKM | |
| SCHEMBL13865824 | 0.83 | MAPT (0.31) | MAPTPKM | |
| SCHEMBL28736752 | 0.65 | ALDH1A1 (0.63) | MAPTMAPK1 | |
| SCHEMBL13865822 | 0.64 | MAPT (0.38) | MAPTPKMMAPK1RAB9AATM | |
| SCHEMBL6753980 | 0.62 | TLR8 (0.40) | MAPTPKMMAPK1RAB9A | |
| SCHEMBL13865840 | 0.60 | MAPT (0.40) | MAPTMAPK1RAB9AATM | |
| SCHEMBL6755245 | 0.60 | TLR8 (0.41) | MAPTPKMMAPK1RAB9A | |
| SCHEMBL13865832 | 0.60 | KDM4E (0.35) | MAPTPKMMAPK1RAB9A | |
| SCHEMBL6756151 | 0.59 | PSEN1 (0.43) | PKMRAB9A | |
| SCHEMBL31448409 | 0.58 | MAPT (0.71) | MAPTPKMMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | NDUFB1, NDUFB6, NDUFB7 | MAPT 4476/4885PKM 3565/4885MAPK1 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.